Roche says Ocre­vus failed Phase 3 study; Sanofi li­cens­es au­toim­mune as­set from Nurix

Plus, news about Sum­it­o­mo Phar­ma, Gilead, Roche, De­sen­tum, In­hi­brx and Pi­la Phar­ma:

Roche’s Ocre­vus fails high-dose study: The Phase 3 study look­ing at a dose …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER